Neuroprotection in Glaucoma Using Calpain-1 Inhibitors: Regional Differences in Calpain-1 Activity in the Trabecular Meshwork, Optic Nerve and Implications for Therapeutics

Author(s): Bharathi Govindarajan, James Laird, Ronald Sherman, Robert G. Salomon, Sanjoy K. Bhattacharya

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 7 , Issue 3 , 2008

Become EABM
Become Reviewer
Call for Editor


Glaucoma is a group of irreversible blinding eye diseases affecting over 70 million people worldwide. Systemic delivery of calpain-1 inhibitors was proposed as a neuroprotection strategy for the prevention of progressive optic nerve damage in glaucoma. We present a general review of calpain-1 and an account of vast differences in processing of calpain- 1 in the trabecular meshwork (TM) and the optic nerve. Calpain-1 accumulates in the glaucomatous TM tissues in vivo. However, calpain-1 activity is substantially lower in the glaucomatous TM compared to controls, apparently owing to partial degradation, and modification by lipid oxidation products such as iso [4]levuglandin E2 (iso [4]LGE2). Treatment of calpain-1 with iso [4]LGE2 in vitro results in covalent modification, inactivation, and resistance to protease digestion. Iso [4]LGE2-modified calpain-1 appeared to undergo ubiquitination in the TM by cellular degradation machinery mediated by ubch1-2, ubch5,6 and E6-AP, E2 and E3 enzymes respectively. In the TM, iso [4]LGE2-modified calpain-1 loading impairs the cellular proteasome activity consistent with competitive inhibition and formation of suicidal high molecular weight aggregates. In contrast, higher calpain-1 activity, that appears to be under translational control, was observed in glaucomatous optic nerve compared to control. Therapeutic neuroprotection strategies using calpain-1 inhibitors will require consideration of such anatomic differences in its activity and biosynthesis.

Keywords: Glaucoma, calpain, trabecular meshwork, isolevuglandin, lipid oxidation, posttranslational modifications, neuroprotection

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [295 - 304]
Pages: 10
DOI: 10.2174/187152708784936644
Price: $65

Article Metrics

PDF: 3